Periodic Reporting for period 1 - SAL ETHVI (Innovative, easily applicable vaccine for poultry industry against five Salmonella serovars: Enteritidis, Typhimurium, Hadar, Virchow and Infantis – SAL ETHVI) Reporting period: 2016-01-01 to 2016-05-31 Summary of the context and overall objectives of the project The main objective of the Phase 1 Feasibility Study was to validate technological and economic viability of our technology and product in view of its potential future commercialization. The feasibility of SAL ETHVI project was fully confirmed during 5 months of Phase 1 execution. Immunolab and NatVet aim at bringing to the global market novel, cost-efficient vaccine that enables easy and effective from the first day of vaccination of chicks. To achieve that goal, we will develop our production technology and commercial network. Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far Our detailed feasibility study covered following tasks:Task 1: In depth market analysis of the broilers marketTask 1.1. Market study: Detailed market study was performed. We have analysed market size in Europe and worldwide, mapped the countries with the biggest poultry production and identified trends on the market. Based on the information gained we have calculated Serviceable Obtainable Market size.Task 1.2. Client/end users study: We have interacted with end users to confirm the market adoption of the vaccine, price acceptance and willingness to pay. Current insights from the market speak of strong interest for the innovative vaccine technology and its consideration as relevant in all of the analyzed countries.Task 1.3. Problem quantification: We have investigated Salmonella incidence in general flock and reduction measures, which gives us extended overview on current situation of Salmonella prevention and occurrence.Task 1.4. Value chain mapping: We have identified hazard points relevant for the food safety perspective and conduct business risk analysis and contingency plans.Task 1.5. Partner search: We have established business relations with companies connected with the poultry industry. They expressed high interest in a future cooperation with Immunolab and NatVet in a field of commercialization of SAL ETHVI.Task 2: Perform operational and technical feasibility studyTask 2.1. Cost-benefit scenario:Having in mind all factors influencing our business, we have analysed in details all cost and benefits that are relevant for our project.Task 2.2. Technical requirements:We have validated different configurations of the prototype for the needs of production of the vaccine in different composition models. Results of validation are positive.Task 2.3. IPR and protection strategy:The certification and legal aspects were assessed. We have investigated in details all aspect of vaccine registration and GMP standarisation. “Freedom-to-Operate analysis” was updated.Task 3: Create an updated business plan Based on the results of the abovementioned tasks, a business plan has been developed to include a detailed marketing/dissemination and commercialization plan, a market research and a financial plan. Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far) Phase 1 execution proved that SAL ETHVI project is feasible and has a great commercial value. Therefore, we plan to apply for the SME Instrumet Phase 2 grant, to continue development of our product and technology to eventually offer it on the market. SAL ETHVI vaccine fighting against 5 Salmonella serotypes will increase food safety and decrease number of gastrointestinal diseases in humans. SAL ETHVI vaccine
